Beyond Air (XAIR) Scheduled to Post Quarterly Earnings on Tuesday

Beyond Air (NASDAQ:XAIR) will be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Beyond Air has set its FY 2025 guidance at EPS.

Beyond Air (NASDAQ:XAIR) last released its quarterly earnings data on Monday, June 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.11. The company had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $0.71 million. Beyond Air had a negative net margin of 5,197.76% and a negative return on equity of 203.12%. During the same period in the previous year, the company earned ($0.67) EPS. On average, analysts expect Beyond Air to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Beyond Air Stock Down 1.6 %

Beyond Air stock traded down $0.01 during trading hours on Tuesday, hitting $0.61. The company had a trading volume of 39,810 shares, compared to its average volume of 529,828. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.80 and a quick ratio of 3.61. Beyond Air has a 1 year low of $0.53 and a 1 year high of $3.90. The company has a 50-day moving average price of $0.91 and a two-hundred day moving average price of $1.33.

Wall Street Analyst Weigh In

XAIR has been the subject of several research reports. BTIG Research cut shares of Beyond Air from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 25th. Truist Financial lowered their price target on shares of Beyond Air from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Finally, Piper Sandler lowered their price target on shares of Beyond Air from $7.00 to $3.50 and set an “overweight” rating for the company in a research report on Tuesday, June 25th.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.